Global Access Archive

Leveraging Value-Based Healthcare Partnerships to Transform Care

In a recent publication of The MedTech Strategist, Suzanne Winter, Americas Region VP for Medtronic Diabetes, discusses our approach to #valuebasedhealthcare — and how we’re leveraging #VBHC to transform diabetes care. Read a short excerpt from the article below: The Medtech Strategist (MTS): Value-based care is a relatively new concept/business model in diabetes management

Learning About Diabetes: Perspective on the Prevalence and Economic Burden of the Disease

WHAT IS DIABETES? There are three major types of diabetes: Type 1 diabetes, is an autoimmune disease, which is generally onset in children and young adults and is characterized by the loss of the pancreas’ ability to produce insulin. Type 2 diabetes is primarily found in adults who have resistance to the action of

Animas Customers: Medtronic is Here to Support You

Dear Animas Customers, Following the recent announcement that Animas will exit the market, we heard from many customers who are understandably anxious about what this means for them. Please know that we’re dedicated to supporting you through this transition and welcoming you to the Medtronic family. Our team is ready to support you and

Proving the Economic Benefits of Professional CGM

Our economic analysis of professional CGM using real-world data was published in the Journal of Medical Economics. With this analysis, Medtronic Diabetes is the first to demonstrate the significant clinical and health economic benefits of professional CGM products – such as iPro™2 – for people living with type 2 diabetes, and healthcare systems. Prior

Medtronic Diabetes Announces Outcomes-Driven Agreement in Bangladesh

I’m excited to announce a new patient-centric partnership which will expand access to our therapies to people living with diabetes in Asia Pacific (APAC). We are partnering with the world’s largest diabetes out-patient hospital – the Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM) – to drive positive health

Medtronic Announces New Outcomes-Based Agreement with Aetna

Today we announced an outcomes-based agreement with Aetna for type 1 and type 2 diabetes patients who currently receive multiple daily insulin injections for their diabetes management. The agreement will measure health outcomes for those patients that choose to transition to pump therapy using a Medtronic insulin pump featuring SmartGuard™ Technology – the only

First Mobile Health Initiative Expands Access to Diabetes Therapy in China

With the largest global diabetes population of 114 million people, China is facing rising healthcare costs associated with poor glucose control. Although one in ten people in China have diabetes, the country lacks the education and resources to improve diabetes management among such a large population. With the evolution of China’s healthcare industry, Chinese

Expanding Global Access Via CGM Reimbursement

Expanding access to our therapy to help more people with diabetes is central to our goal of transforming diabetes care for greater freedom and better health. In many parts of the world, insurance does not cover continuous glucose monitoring (CGM), despite clear evidence the technology has clinical and economic benefits. Together, we face a

Project 6 – Strengthening Our Communities

I am so proud of our employees’ generosity. While we support our communities throughout the year– fundraising and participating in walks for the JDRF and ADA, among other activities and organizations– this year, we had phenomenal participation in Project 6. Project 6 is Medtronic’s month-long global effort to support the sixth tenet of our

Why China?

In January 2016, we signed a long-term partnership with the Chengdu municipal government to provide better diabetes management for the growing – and underserved – diabetes population in China. So, why China? According to the International Diabetes Federation, there are 415 million people in the world living with diabetes.[i] That’s a staggering number. Twenty-five